Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID 🚨JUST DROPPED YESTERDAY and rips open the black box of Long COVID: Viral persistence up to at least 24 months. Fibrin microclots that laugh at fibrinolysis. Autoimmune storm. Mitochondrial sabotage. An up-to-date full mechanistic map is finally here! No more guessing. This changes everything, let’s dig into this overview👇, better yet…..read it yourself!! #MustRead ➡️Global Impact & Context: - Long COVID (PASC) affects >400 million people worldwide, incurring >$1 trillion in annual economic costs, - Core symptoms, debilitating fatigue, cognitive dysfunction (“brain fog”), sleep disturbances, and post-exertional malaise (PEM) in 50–80% of cases, persist months to years’ post-infection, with a mechanistic overlap to ME/CFS, ➡️Core Mechanisms: 1. Immune Dysregulation: - Persistent systemic inflammation features elevated cytokines (IL-6, TNF-α, IL-1β) detectable up to 14 months, driving T-cell exhaustion (reduced CD8+ IFN-γ/TNF-α production) and monocyte activation (COX-2, IL-8Rβ, CXCR6), - Autoantibodies (anti-GPCR, anti-PITX2, anti-FBXO2, ANA/ENA) persist 12–14 months and correlate directly with fatigue, dyspnoea, palpitations, and cognitive impairment with molecular mimicry, gut dysbiosis and latent herpesvirus reactivation (EBV, HHV-6) amplifying autoimmunity, 2. Viral Persistence & Reactivation: - SARSCoV2 RNA, spike protein, and antigens remain detectable in brain, muscle, gut and plasma up to 14–24 months in ~60% of cases, fuelling chronic low-grade inflammation, - EBV/CMV reactivation signatures are common with spatial transcriptomics highlighted as a possible next tool to map tissue reservoirs, 3. Endothelial/Microvascular Pathology: - Glycocalyx shedding (elevated SDC-1), capillary rarefaction and endothelin-1 elevation create a pro-thrombotic state, - Platelet hyperactivation releases vWF/FVIII, forming anomalous fibrin(ogen) microclots that resist fibrinolysis and these circulate and fragment during exertion, causing hypoxia, ischaemia-reperfusion injury, and PEM, 4. Autonomic Dysfunction: - Present in ~50% of patients (POTS predominant), driven by hypovolaemia (70%), small-fibre neuropathy (20–40%), vagus-nerve damage and microclot-induced compensatory tachycardia with 4-fold norepinephrine spikes, 5. Mitochondrial Impairment & Neuroinflammation: - Skeletal-muscle biopsies show reduced respiration, cytochrome c oxidase activity and WASF3-mediated supercomplex disruption, producing rapid lactate rise and PEM within 48 h, - Systemic cytokines breach the blood–brain barrier, sustaining microglial activation and cognitive sequelae, ➡️Diagnostic & Therapeutic Gaps: - No validated biomarkers or subtype-specific criteria exist. - Graded exercise is contraindicated. - Observational promise exists for IVIg, low-dose naltrexone and apheresis, but large RCTs are urgently required. ➡️Future Priorities: Calls for subtype-specific research, large-scale RCTs, advanced techniques (spatial transcriptomics, proteomics), and interdisciplinary collaboration to develop precision diagnostics and therapies. ‼️This exceptional review delivers a masterful, evidence-based roadmap that not only clarifies Long COVID’s complex pathophysiology but stimulates the scientific community toward urgently needed mechanistic breakthroughs and effective, patient-centred interventions. ‼️Bottom line: Long COVID is not a single disease but a complex, multisystem condition that can impact your life seriously! #AvoidSars2 #AvoidReinfections A huge thanks to all authors, @DrMark_Faghy @DavidJoffe64 @PutrinoLab @DaniBeckman @resiapretorius @Sunny_Rae1 are only some of them!👏👏 nature.com/articles/s43856-0…